Items tagged with Global TB response

IJTLD May 2017 issue now online (post)

The International Journal of Tuberculosis and Lung Disease (IJTLD) is the official publication of the International Union Against Tuberculosis and Lung Disease (The Union).

Tuberculosis innovations mean little if they cannot save lives (post)

In a paper published in eLife, Madhukar Pai and Jennifer Furin summarized the uptake of new TB tools such as GeneXpert, bedaquiline and delamanid, and identified the main barriers to scale-up and patient access.

Aidspan publishes new issue of ‘Global Fund Observer’ (post)

Aidspan: Global Fund Observer

Antibiotic resistance has a language problem (post)

A failure to use words clearly undermines the global response to antimicrobials' waning usefulness. Standardize terminology, urge Marc Mendelson and colleagues in a comment published in Nature.

Unitaid joins UN group on antimicrobial resistance (post)

Geneva, 10 May 2017 – Unitaid has joined the United Nations coordination group on antimicrobial resistance, recognizing the growing public health challenge it poses in the fight against HIV/AIDS, tuberculosis and malaria.

Aidspan publishes new issue of ‘Global Fund Observer’ (post)

Aidspan: Global Fund Observer

MSF open letter to G20 Health Ministers highlights 3 global health priority areas (post)

Médecins Sans Frontières: Open letter from MSF to the Meeting of the G20 Health Ministers

Report outlines priorities for U.S. global health role (post)

New report recommends priority actions to achieve global health security, protect U.S. position as global health leader, and safeguard billions of dollars in health investments.

Global TB Caucus consultation on the role of parliamentarians in ending TB (post)

The Global TB Caucus is seeking to better understand what the role of parliamentarians should be in relation to the Global Ministerial Conference on TB in November 2017 and the United Nations High-Level Meeting on TB in 2018, what should be the primary objectives, and what the desired outcome should look like.

New alliance to drive and measure industry progress to curb antimicrobial resistance (post)

• New Industry Alliance brings together research-based pharmaceutical companies, generics, biotech and diagnostic companies, to drive and measure industry progress to curb antimicrobial resistance.
• The AMR Industry Alliance will ensure that signatories collectively deliver on the commitments made in the Declaration (January 2016) and the Roadmap (September 2016) and will measure industry’s progress in the fight against AMR.
• The Alliance will develop a reporting mechanism to track progress, identify gaps and set targets for the future. Its progress reports will also help to assess what are the key hurdles impeding actions outside of industry’s sole control on reducing antimicrobial resistance and facilitate collaboration between the public and private sector.